Therapy Areas: Diabetes
Peru to resume COVID-19 vaccine trials of China's Sinopharm after lifting of suspension
17 December 2020 -

The Health Minister of Peru, Pilar Mazzetti, announced on 16 December 2020 that COVID-19 vaccine trials of Chinese healthcare group China National Pharmaceutical Group Corp (Sinopharm) can resume in Peru, CNN reported on Thursday.

Mazzetti was quoted as saying during a Cabinet news briefing on 16 December: "The situation has been clarified and the suspension has been lifted today."

On 12 December 2020, Peru's clinical trials of the Sinopharm vaccine were temporarily suspended by the Peruvian National Institute of Health after a 64-year-old patient, with a history of diabetes, reported a decrease in muscle strength in his legs.

At that time, German Malaga, the head of clinical trials at Sinopharm laboratories in Peru, said that the reason for the symptoms had not yet been determined.

Mazzetti gave no further details as to whether or not the patient's symptoms were linked to the vaccine candidate, CNN added.

Login
Username:

Password:


Related Headlines

Colombia approves Pfizer-BioNTech COVID-19 vaccine for emergency use

VisionQuest Biomedical Inc wins FDA 510(k) clearance to market the Image Quality Analyzer software

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80m Patient Encounters in the US Annually

Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS

The FDA approves first generic glucagon to treat severe hypoglycemia to improve competition and access to more affordable medicines

Health Canada Accepts Vertex New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis

EOM Pharmaceuticals Files Pre-IND Meeting Request with US FDA to Evaluate Plans for a Phase 2 Clinical Trial of Its Investigational Dual-Acting, Broad-Spectrum Immunomodulator in COVID-19 Patients

Oramed Pharmaceuticals reveals results from proof-of-concept study for oral leptin

US FDA Approves Supplemental New Drug Application for Takeda's ICLUSIG (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML

Peru to resume COVID-19 vaccine trials of China's Sinopharm after lifting of suspension

Glytec Publishes COVID-19 Research to Study the 'Opportunity Window' for Treating Hospitalized Patients with Diabetes or Hyperglycemia

Medtronic names new executive vice president and president, Cardiovascular Portfolio

Peru suspends trail of Sinopharm's COVID-19 vaccine trial after patient reports decrease in muscle strength in his legs

Tobin Scientific, PHCbi Collaborate on Solution for Regional Distribution of COVID-19 Vaccine to Address Ultra Low Temperature Requirements

Genprex Completes Manufacturing Technology Transfer for Novel Gene Therapy